Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Cameroon says Russia has confirmed 16 Cameroonian soldiers died in Ukraine - 2EU waters down plans to end new petrol and diesel car sales by 2035
- 3Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- 46 Well known Nissan Vehicles in the U.S.
- 5Good ways to respond if your kid brings home less-than-ideal grades
- 4 astronauts are now on their path to the moon. Here’s what happens next
- WHO issues guidance on GLP-1 drugs for obesity
- Why the Houthis waited until now to strike
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- Unsold Rams May Be Less expensive Than You Suspect
- We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- Find the Abilities Required for Advanced Advertising Position
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
